Abstract
Crystallisation and recrystallisation are important unit operations in the pharmaceutical industry. In our experience cooling crystallisations are preferred to other ways of generating supersaturation because they are quicker to develop and provide better control of purity and polymorph and particle properties. There is, however, a perception that the yield from cooling crystallisations is low. This work presents an approach to designing cooling crystallisations based on a review of the temperature dependence of solubility for over 100 systems. This methodology is demonstrated with a case study of an in-house development compound. The conclusion is that cooling crystallisations are generally viable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
